Kits Eyecare (TSE:KITS - Get Free Report) had its price target lowered by equities researchers at Canaccord Genuity Group from C$23.00 to C$22.00 in a research note issued to investors on Thursday,BayStreet.CA reports. The firm currently has a "buy" rating on the stock. Canaccord Genuity Group's target price indicates a potential upside of 92.48% from the stock's previous close.
Several other analysts have also recently weighed in on the company. ATB Cormark Capital Markets lowered their price target on Kits Eyecare from C$20.00 to C$16.75 and set a "speculative buy" rating on the stock in a report on Thursday. Stifel Nicolaus decreased their price objective on shares of Kits Eyecare from C$24.00 to C$21.00 and set a "buy" rating on the stock in a research report on Thursday. Finally, Desjardins lowered their target price on shares of Kits Eyecare from C$25.00 to C$23.00 and set a "buy" rating on the stock in a research note on Thursday. Four research analysts have rated the stock with a Buy rating, According to MarketBeat, Kits Eyecare has a consensus rating of "Buy" and an average target price of C$20.69.
Check Out Our Latest Research Report on KITS
Kits Eyecare Price Performance
Shares of KITS traded down C$0.95 during mid-day trading on Thursday, reaching C$11.43. 306,356 shares of the stock traded hands, compared to its average volume of 115,911. The firm has a market capitalization of C$388.51 million, a P/E ratio of 127.00 and a beta of 0.46. Kits Eyecare has a 1 year low of C$11.12 and a 1 year high of C$22.56.
Kits Eyecare (TSE:KITS - Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The company reported C$0.06 earnings per share (EPS) for the quarter. The business had revenue of C$57.47 million during the quarter.
About Kits Eyecare
(
Get Free Report)
KITS TSX: KITS is one of the world's fastest growing eyecare providers, offering high-quality, affordable prescription glasses and contact lenses through its vertically integrated digital platform. With advanced in-house lens manufacturing, an industry-leading digital fit experience powered by OpticianAI, and thousands of 5-star customer reviews, KITS is redefining how Canadians experience eyecare. Designed in Canada. Delivered worldwide.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Kits Eyecare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kits Eyecare wasn't on the list.
While Kits Eyecare currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.